A STUDY ON THE ROLE OF THE RB1 GENE AS A PROGNOSTIC FACTOR IN UNTREATED PATIENTS WITH B-CHRONIC LYMPHOCYTIC LEUKEMIA

Chronic lymphocytic leukemia (CLL) is one of the most common leukemias in adults. After 2000, the FDA approved drugs for its treatment with mechanisms of action different from those of the then-known cytostatics. This new therapeutic approach, employing targeted therapy, is based on a better underst...

Full description

Saved in:
Bibliographic Details
Main Authors: Vanya Slavcheva (Author), Svetlana Angelova (Author), Georgi Balatzenko (Author), Tzvetan Lukanov (Author), Pencho Tonchev (Author)
Format: Book
Published: Peytchinski Publishing, 2022-10-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_ca093bc1ff1a4437a9ccb18b35cf5e4b
042 |a dc 
100 1 0 |a Vanya Slavcheva  |e author 
700 1 0 |a Svetlana Angelova  |e author 
700 1 0 |a Georgi Balatzenko  |e author 
700 1 0 |a Tzvetan Lukanov  |e author 
700 1 0 |a Pencho Tonchev  |e author 
245 0 0 |a A STUDY ON THE ROLE OF THE RB1 GENE AS A PROGNOSTIC FACTOR IN UNTREATED PATIENTS WITH B-CHRONIC LYMPHOCYTIC LEUKEMIA 
260 |b Peytchinski Publishing,   |c 2022-10-01T00:00:00Z. 
500 |a 10.5272/jimab.2022284.4622 
500 |a 1312-773X 
520 |a Chronic lymphocytic leukemia (CLL) is one of the most common leukemias in adults. After 2000, the FDA approved drugs for its treatment with mechanisms of action different from those of the then-known cytostatics. This new therapeutic approach, employing targeted therapy, is based on a better understanding of the biology and key pathogenetic mechanisms driving the development and progression of the disease. Deletion of the long arm of chromosome 13 is one of the most frequently described cytogenetic aberrations among CLL patients, the prognostic value of which is still debated, given that part of the tumor suppressor genes are located in this chromosome. Our study aimed to investigate the frequency of deletions affecting the retinoblastoma gene (RB1) and their impact on the time to first treatment (TTFT) in untreated B-CLL patients. The cohort included 40 patients with a confirmed diagnosis of CLL and deletion of the DLEU1 gene. Fluorescence in situ hybridization (FISH) was used to determine cytogenetic aberrations affecting the DLEU1 and Rb1 genes. The difference in time to first treatment in patients with/without deletion in the Rb1 gene was determined based on the log-rank test. In our study, we found a shorter time to initiation of first treatment in patients with a deletion in the Rb1 gene. Future clinical studies, including a more significant number of patients with an isolated deletion in the Rb1 gene, would confirm or reject the importance of the mentioned aberration as a prognostic factor and the necessity of its examination in routine practice. 
546 |a EN 
690 |a chronic lymphocytic leukemia 
690 |a prognosis 
690 |a tumor suppressor gene 
690 |a Dentistry 
690 |a RK1-715 
690 |a Medicine (General) 
690 |a R5-920 
655 7 |a article  |2 local 
786 0 |n Journal of IMAB, Vol 28, Iss 4, Pp 4622-4625 (2022) 
787 0 |n https://www.journal-imab-bg.org/issues-2022/issue4/2022vol28-issue4-4622-4625.pdf 
787 0 |n https://doaj.org/toc/1312-773X 
856 4 1 |u https://doaj.org/article/ca093bc1ff1a4437a9ccb18b35cf5e4b  |z Connect to this object online.